Guardant Health and Natera both reported quarter-strength diagnostics momentum tied to oncology testing—signals that continue to push liquid biopsy adoption beyond early-stage research. Guardant said Q1 2026 revenue grew 48% year over year to $301.7 million and raised full-year guidance, with volume growth and reimbursement dynamics cited as key drivers. Guardant highlighted growth in minimal residual disease testing, including a doubling in Reveal volumes, and said it has submitted data packages to CMS’s MolDx program for breast cancer surveillance and immunotherapy and chemotherapy monitoring. The company also described upgrades to its oncology tests that could broaden conversion of non-users. Separately, Natera increased 2026 outlook after Q1 revenue jumped 39% year over year, driven by both clinical oncology and women’s health franchises. Natera said it delivered its million-unit milestone run rate in a single quarter and pointed to growth in minimal residual disease testing, plus adoption of its expanded Fetal Focus product.